Gulam A. Manji, MD, PhD

home / authors / gulam-a-manji-md-phd

Articles

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

Gulam A. Manji, MD, PhD
October 2nd 2019

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Read More

Dr. Manji on Treatment for NTRK Fusion+ CRC

Dr. Manji on Treatment for NTRK Fusion+ CRC

Gulam A. Manji, MD, PhD
September 18th 2019

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

Read More

Dr. Manji on Treatment for Right-Sided Tumors in CRC

Dr. Manji on Treatment for Right-Sided Tumors in CRC

Gulam A. Manji, MD, PhD
September 4th 2019

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

Read More

Dr. Manji on Treatment for BRAF-Mutant CRC

Dr. Manji on Treatment for BRAF-Mutant CRC

Gulam A. Manji, MD, PhD
August 16th 2019

Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.

Read More

Dr. Manji on Predictive or Prognostic Biomarkers in GI Cancers

Dr. Manji on Predictive or Prognostic Biomarkers in GI Cancers

Gulam A. Manji, MD, PhD
July 15th 2019

Gulam A. Manji, MD, PhD, discusses the role of finding biomarkers in patients with gastrointestinal cancers.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data